Analysis of literature-derived duplicate records in the FDA Adverse Event Reporting System (FAERS) database

被引:1
|
作者
Han, Weiru [1 ]
Morris, Robert [2 ,3 ]
Bu, Kun [1 ]
Zhu, Tianrui [2 ]
Huang, Hong [4 ]
Cheng, Feng [2 ,3 ]
机构
[1] Univ S Florida, Coll Art & Sci, Dept Math & Stat, Tampa, FL 33620 USA
[2] Univ S Florida, Taneja Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33613 USA
[3] Univ S Florida, Coll Publ Hlth, Dept Biostat & Epidemiol, Tampa, FL 33613 USA
[4] Univ S Florida, Sch Informat, Tampa, FL 33620 USA
基金
美国国家卫生研究院;
关键词
pharmacovigilance; PubMed; adverse drug events; text comparison; FAERS Dashboard; DEMENTIA; MEDWATCH; PATIENT;
D O I
10.1139/cjpp-2024-0078
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The FDA Adverse Event Reporting System (FAERS) is a large-scale repository of reports concerning adverse drug events (ADEs). The same published clinical study or report may be reviewed by multiple companies or healthcare professionals and reported separately to the FDA, leading to a significant presence of duplicate reports in FAERS. These duplicate records can result in the identification of false associations between a given drug and an ADE. In this study, we first assessed the consistency of drug and ADE information in FAERS reports from Alzheimer's disease patients. Our findings showed greater congruence in drug-related information compared to ADE-related information, likely due to the greater heterogeneity and variety of terms or phrases used to describe ADEs. We then demonstrated that text comparison methods are effective in identifying duplicate records based on literature citations, testing 10 different comparison functions for their overall efficacy. Token-based methods (such as COSINE, QGRAM, and JACCARD), edit-based approaches (including OSA, LV, and DL), and sequence-based techniques like LCS have proven highly effective in accurately detecting identical publications within free text, demonstrating both high sensitivity and specificity. These results offer valuable insights for identifying duplicate FAERS reports and improving the reliability of detected associations between drugs and ADEs.
引用
收藏
页码:56 / 69
页数:14
相关论文
共 50 条
  • [31] Comparing Common Therapies in Polycythemia Vera (PV): A Disproportionality Analysis in the FDA Adverse Event Reporting System (FAERS) Database
    Snopek, Frank
    Seddighzadeh, Ali
    Flynn, Megan
    Cai, Ling-Yu
    Chen, Esther
    Shih, Weichung Joe
    Qin, Albert
    Urbanski, Raymond W.
    BLOOD, 2023, 142
  • [32] A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
    Zou, Fan
    Zhu, Chengyu
    Lou, Siyu
    Cui, Zhiwei
    Wang, Dan
    Ou, Yingyong
    Wang, Li
    Chen, Junyou
    Lan, Yuanbo
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [33] Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
    Ma, Zhuo
    Pei, Jie
    Sun, Ximu
    Liu, Lihong
    Lu, Wenchao
    Guo, Qixiang
    Lyu, Jiayou
    Liu, Yuwei
    Zhang, Yuhui
    Zhao, Zhixia
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [34] Severe hypoglycemia in children treated with nadolol: A case report and FDA adverse event reporting system (FAERS) database analysis
    Bergamaschi, Francesco
    Fumagalli, Mara
    Mannarino, Savina
    Carlucci, Patrizia
    Radice, Sonia
    Gringeri, Michele
    Mosini, Giulia
    Carnovale, Carla
    Battini, Vera
    Fabiano, Valentina
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2021, 59 (04) : 333 - 340
  • [35] The Antidepressant Effects of Hypoglycaemic Agents: New Insights from an Analysis of the FDA Adverse Event Reporting System (FAERS) Database
    Carnovale, C.
    Battini, V.
    Gringeri, M.
    Mosini, G.
    Guarnieri, G.
    Radice, S.
    Clementi, E.
    Manen, R. P. V.
    DRUG SAFETY, 2022, 45 (10) : 1285 - 1285
  • [36] Adverse event signal analysis of remimazolam using the FDA adverse event reporting system database
    Liu, Hongtao
    Li, Zhaoyu
    Yan, Su
    Ming, Shaopeng
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2025, 69 (03)
  • [37] A Decade of Nintedanib: An Analysis of the FDA Adverse Event Reporting System Database
    Niranjan, S.
    Rao, A.
    Virk, S. T.
    Sarangdhar, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [38] Adverse events associated with azithromycin and clarithromycin in adults aged ≥65: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database
    Zhang, Zhenpo
    He, Jiaxin
    Liang, Yankun
    Wang, Yuting
    Zheng, Jingping
    Ma, Lin
    Su, Ling
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [39] Severe cutaneous adverse reactions associated with antifungal agents: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) database
    Shan, Huifang
    Wei, Chunyan
    Zhang, Jingyi
    Wu, Bin
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [40] A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)
    Xue, Zehu
    Liu, Xi
    Liu, Qifeng
    Yang, Xiuming
    Yu, Lixia
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):